SCHEMBL2651995

SCHEMBL2651995

C#Cc1cc(C(F)(F)F)ccc1Cl

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGDR2 Q9Y5Y4 1/20 0.43
MCL1 Q07820 3/20 0.41
PDE2A O00408 2/20 0.41
TSHR P16473 2/20 0.39
ALDH1A1 P00352 4/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
ATM Q13315 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
HTT P42858 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
MRGPRX4 Q96LA9 1/20 0.36
HSD17B10 Q99714 1/20 0.36
MAPT P10636 1/20 0.36
JAK2 O60674 1/20 0.36
JAK1 P23458 1/20 0.36
TYK2 P29597 1/20 0.36
ADRA2A P08913 1/20 0.36
HTR2A P28223 1/20 0.35
SLC6A4 P31645 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15541043 0.84 PDE2A (0.44) PTGDR2MCL1PDE2ATSHRALDH1A1
SCHEMBL31568536 0.84 PDE2A (0.44) PTGDR2MCL1PDE2ATSHRALDH1A1
SCHEMBL384969 0.80 AR (0.47) PTGDR2PDE2AALDH1A1HTTSMN1; SMN2
SCHEMBL29837271 0.80 AR (0.47) PTGDR2PDE2AALDH1A1HTTSMN1; SMN2
SCHEMBL16951053 0.80 PDE2A (0.41) PTGDR2MCL1PDE2ATSHRALDH1A1
SCHEMBL2515789 0.80 PTGDR2 (0.43) PTGDR2MCL1PDE2ATSHRALDH1A1
SCHEMBL3253124 0.80 PDE2A (0.41) PTGDR2MCL1PDE2ATSHRALDH1A1
SCHEMBL20455634 0.78 CES2 (0.46) PTGDR2PDE2ATSHRMRGPRX4HSD17B10
SCHEMBL78780 0.77 ALDH1A1 (0.51) PTGDR2MCL1PDE2AALDH1A1MEN1
SCHEMBL2432042 0.76 ALDH1A1 (0.42) TSHRALDH1A1MEN1KMT2AATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1773330-B1 SUBSTITUTED PYRAZOLES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE MERCK SHARP & DOHME (US) 2010-05-26 EP disclosed
US-7625938-B2 Substituted pyrazoles, compositions containing such compounds and methods of use MERCK & CO., INC. (US) 2009-12-01 US disclosed
EP-1773330-A4 SUBSTITUTED PYRAZOLES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE MERCK & CO INC (US) 2009-01-21 EP disclosed
US-20080108620-A1 Substituted Pyrazoles, Compositions Containing such Compounds and Methods of Use MERCK & CO., INC. (US) 2008-05-08 US disclosed
CN-1993124-A Substituted pyrazoles, compositions containing such compounds and methods of use MERCK & CO INC (US) 2007-07-04 CN disclosed
EP-1773330-A2 SUBSTITUTED PYRAZOLES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE Merck & Co., Inc. (US) 2007-04-18 EP disclosed
WO-2006014618-A2 SUBSTITUTED PYRAZOLES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE MERCK & CO., INC. (US) 2006-02-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080108620-A1 Substituted Pyrazoles, Compositions Containing such Compounds and Methods of Use GLP1R, GCGR, GPR119 PTGDR2 114/4885MCL1 2968/4885PDE2A 254/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.